Recently, the phase III IMpower133 trial showed that adding the programmed death-ligand 1 (PD-L1) inhibitor, atezolizumab, to chemotherapy as the first-line therapy for ES-SCLC could improve the progression-free survival (PFS) and overall survival (OS) of patients (6). Here, CD274 is linked to small cell lung carcinoma.